论文部分内容阅读
目的探讨力扑素联合奈达铂方案治疗晚期非小细胞肺癌(NSCLC)临床效果及患者死亡相关影响因素。方法选取2010年6月至2012年6月间收治的80例NSCLC患者,按照治疗方法分为观察组和对照组,每组40例。观察组给予力扑素联合奈达铂方案治疗,对照组给予力扑素联合顺铂方案治疗。比较两组患者的治疗效果、不良反应、1年生存率以及患者死亡因素。结果观察组患者的总有效率为42.5%(17/40),对照组为37.5%(15/40),差异无统计学意义(P>0.05);观察组患者的呕吐、关节肌疼痛和周围神经炎的发生率分别为17.5%(7/40)、7.5%(3/40)和10.0%(4/40),均显著低于对照组的37.5%(15/40)、25.0%(10/40)和27.5%(11/40,P<0.05);观察组患者1年生存率为65.0%(26/40),对照组为60.0%(24/40),差异无统计学意义(P>0.05);观察组患者的Karnofsky评分为(75±11)分,高于对照组(72±9分,P<0.05);年龄、病情程度、腺癌、积液、肺部感染是患者死亡的重要危险因素(P<0.05)。结论两种治疗方案近期效果无显著差异,但力扑素联合奈达铂方案减轻了患者的不良反应;应积极应对危险因素,提高患者生存时间。
Objective To investigate the clinical effects of forcepsin combined with nedaplatin in the treatment of advanced non-small cell lung cancer (NSCLC) and the related factors of death. Methods Eighty patients with NSCLC who were admitted between June 2010 and June 2012 were divided into observation group and control group according to the treatment method, 40 cases in each group. The observation group was treated with forcebus combined with nedaplatin and the control group with forceprotin combined with cisplatin. The treatment effect, adverse reaction, 1-year survival rate and patient’s death factor were compared between the two groups. Results The total effective rate was 42.5% (17/40) in the observation group and 37.5% (15/40) in the control group, with no significant difference (P> 0.05). The vomiting, The incidence of neuritis was 17.5% (7/40), 7.5% (3/40) and 10.0% (4/40), respectively, which were significantly lower than those in the control group (37.5%, 25.0%, 10% / 40) and 27.5% (11/40, P <0.05). The 1-year survival rate was 65.0% (26/40) in the observation group and 60.0% (24/40) in the control group, with no significant difference > 0.05). The Karnofsky score of the observation group was (75 ± 11) points higher than that of the control group (72 ± 9 points, P <0.05). The age, severity of illness, adenocarcinoma, effusion and lung infection were the patients died The significant risk factors (P <0.05). Conclusion There is no significant difference between the two treatment regimens in the near future. However, the combination of forceopril and nedaplatin reduces the adverse reactions in patients. It should respond positively to risk factors and improve the survival time of patients.